BioSpace News Archive

Phathom Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced an underwritten public offering of 5,000,000 shares of its common stock.

BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced its intention to effect a 1-for-4,000 reverse split of its common stock in preparation for the planned listing of the Company’s securities on The Nasdaq Capital Market.

Cortexyme, Inc. (Nasdaq: CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis).

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced it plans to release its third quarter 2021 financial results after the market closes on Tuesday, November 9, 2021.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433.

Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today provided a corporate update and reported financial results for its fiscal year ended June 30, 2021.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy™.

4D Molecular Therapeutics (Nasdaq: FDMT), announced today that it has commenced an underwritten public offering of 4,500,000 shares of its common stock.

Valneva SE announced its intention to issue and sell, subject to market conditions, 5,500,000 of its ordinary shares in a global offering to specified categories of investors comprised of a public offering of its American Depositary Shares, each representing two ordinary shares, in the United States and a concurrent private placement of its ordinary shares in certain jurisdictions outside of the United States.

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-based financial markets.